- BioNexus Gene Lab Corp. has entered a $500 million Equity Purchase Agreement with ARC Group International Ltd., giving the company discretionary access to capital over 36 months.
- The funding will support commercialisation of the VitaGuard MRD platform, expansion into CDMO services and development of therapeutic programmes.
BioNexus Gene Lab Corp. has signed a $500 million Equity Purchase Agreement with ARC Group International Ltd. to support its precision oncology, CDMO and therapeutic development initiatives across Southeast Asia. The company said the facility provides long-term, discretionary access to capital to advance its strategic programmes, including the commercial roll-out of the VitaGuard minimal residual disease platform and the addition of regional contract development and manufacturing services.
Under the agreement, BioNexus Gene Lab may issue and sell registered common stock to ARC over a 36-month period. As consideration for ARC’s commitment, the company issued 175,000 shares at the closing price of $4.32 on 26 November 2025. ARC is restricted from owning more than 9.99% of BioNexus Gene Lab’s outstanding shares and is prohibited from short-selling or hedging the company’s securities. Shares may not be sold prior to the filing of a registration statement. The facility complements the company’s $20 million At-The-Market programme.
“This commitment from ARC strengthens our capital position at a pivotal time for BGLC, referencing the company’s licence agreement for the VitaGuard MRD platform and its ongoing transition into a CDMO capable of supporting high-value bioprocessing and manufacturing. He added that the facility is intended to support milestone-driven initiatives.”
Chief Executive Officer, Sam Tan
The company recently executed a licensing agreement with Fidelion Diagnostics to commercialise the VitaGuard assay across Malaysia, Singapore, Indonesia and Thailand. The platform supports early cancer detection, recurrence monitoring and treatment decision-making. The new capital facility is intended to help advance clinical adoption and regulatory activities.
The company is also expanding into CDMO services, including biologics production and assay manufacturing. The facility will support investment in quality systems, manufacturing capacity and technical capabilities aligned with global contract manufacturing standards. Additionally, the capital may support progress on the company’s partnership initiative with BirchBioMed for FS2, a therapeutic candidate targeting fibrosis, hypertrophic scarring and skin regeneration.
